Roche, based in Basel, Switzerland, has announced plans to restructure its manufacturing network for small molecules to address current underutilization as a result of its evolving portfolio. A new generation of specialized medicines based on small molecules requires novel manufacturing technologies and will be produced in lower volumes than traditional medicines.
As a result, Roche plans to exit four manufacturing sites in Clarecastle, Ireland; Leganes, Spain; Segrate, Italy; and Florence, S.C. In an effort to minimize job reductions, the company is actively looking into divestment opportunities for those facilities.
In order to manufacture a new generation of specialized medicines based on small molecules, Roche will further invest 300 million Swiss francs ($299 million) into a dedicated facility in Kaiseraugst, Switzerland, to support future technology requirements. The investment will strengthen the company’s development and launch capabilities.
Roche will immediately begin discussions with employee representatives in the respective countries, and will conduct the consultation process in an open and socially responsible manner. Transition will begin in 2016 and is planned to end by 2021. Affected employees will be notified as soon as possible and will receive appropriate support during the transition.